RNA aptamer probes as optical imaging agents for the detection of amyloid plaques

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Farrar, Christian T ^a   William, Christopher M ^a   Hudry, Eloise ^a   Hashimoto, Tadafumi ^a   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APTAMER; RNA APTAMER BETA55; UNCLASSIFIED DRUG; RNA PROBE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN TISSUE; CONTROLLED STUDY; DOT HYBRIDIZATION; EX VIVO STUDY; FLUORESCENCE IMAGING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOLECULAR PROBE; MOUSE; MULTIMODAL IMAGING; NONHUMAN; PROTEIN AGGREGATION; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; TRANSGENIC MOUSE; ANIMAL; BASE PAIRING; GENETICS; IMMUNOBLOTTING; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; RNA PROBE; ULTRASTRUCTURE; WESTERN BLOTTING;

ALZHEIMER DISEASE; ANIMALS; APTAMERS, NUCLEOTIDE; BASE PAIRING; BASE SEQUENCE; BLOTTING, WESTERN; HUMANS; IMMUNOBLOTTING; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OPTICAL IMAGING; PLAQUE, AMYLOID; RNA PROBES;

EID: 84896354009     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089901     Document Type: Article

References (52)

1. Jayasena SD (1999) Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45: 1628-1650.
2. Nimjee SM, Rusconi CP, Sullenger BA (2005) Aptamers: an emerging class of therapeutics. Annu Rev Med 56: 555-583. (Pubitemid 40299797)
3. Que-Gewirth NS, Sullenger BA (2007) Gene therapy progress and prospects: RNA aptamers. Gene Ther 14: 283-291. (Pubitemid 46231922)
4. Thiel KW, Giangrande PH (2009) Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 19: 209-222.
5. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
6. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
7. Jenison RD, Gill SC, Pardi A, Polisky B (1994) High-resolution molecular discrimination by RNA. Science 263: 1425-1429. (Pubitemid 24137828)
8. Hicke BJ, Stephens AW (2000) Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest 106: 923-928.
9. Bunka DHJ, Stockley PG (2006) Aptamers come of age - at last. Nat Rev Microbiol 4: 588-596. (Pubitemid 44317021)
10. Cheng C, Chen YH, Lennox KA, Behlke MA, Davidson BL (2013) In vivo SELEX for Identification of Brain-penetrating Aptamers. Mol Ther Nucleic Acids 2: e67.
11. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, et al. (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17: 1503-1510. (Pubitemid 32217559)
12. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101: 1172-1184.
13. Ono K, Yamada M (2011) Low-n oligomers as therapeutic targets of Alzheimer's disease. J Neurochem 117: 19-28.
14. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453.
15. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, et al. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27: 796-807. (Pubitemid 46174498)
16. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, et al. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866-2875. (Pubitemid 46438992)
17. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
18. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-357.
19. Lesné S, Kotilinek L, Ashe KH (2008) Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 151: 745-749.
20. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, et al. (2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106: 4012-4017.
21. Koffie RM, Hashimoto T, Tai H-C, Kay KR, Serrano-Pozo A, et al. (2012) Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain 135: 2155-2168.
22. DaRocha-Souto B, Scotton TC, Coma M, Serrano-Pozo A, Hashimoto T, et al. (2011) Brain oligomeric β-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp Neurol 70: 360-376.
23. Kayed R, Glabe CG (2006) Conformation-dependent anti-amyloid oligomer antibodies. Meth Enzymol 413: 326-344. (Pubitemid 44528698)
24. Georganopoulou DG, Chang L, Nam J-M, Thaxton CS, Mufson EJ, et al. (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 102: 2273-2276. (Pubitemid 40279365)
25. PirttiläT, Kim KS, Mehta PD, Frey H, Wisniewski HM (1994) Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sci 127: 90-95. (Pubitemid 24372529)
26. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489. (Pubitemid 36444329)
27. Lafaye P, Achour I, England P, Duyckaerts C, Rougeon F (2009) Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol Immunol 46: 695-704.
28. O'Nuallain B, Wetzel R (2002) Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 99: 1485-1490. (Pubitemid 34136519)
29. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, et al. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegeneration 2: 18.
30. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, et al. (2007) Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 100: 23-35. (Pubitemid 46085837)
31. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, et al. (2006) Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281: 4292-4299. (Pubitemid 43847859)
32. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, et al. (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7: 369-372. (Pubitemid 32224356)
33. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. (2004) Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319. (Pubitemid 38269583)
34. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, et al. (2002) Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61: 797-805. (Pubitemid 35001352)
35. Ylera F, Lurz R, Erdmann VA, Fürste JP (2002) Selection of RNA aptamers to the Alzheimer's disease amyloid peptide. Biochem Biophys Res Commun 290: 1583-1588. (Pubitemid 34687439)
36. Rahimi F, Murakami K, Summers JL, Chen C-HB, Bitan G (2009) RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity. PLoS ONE 4: e7694.
37. Takahashi T, Tada K, Mihara H (2009) RNA aptamers selected against amyloid beta-peptide (Abeta) inhibit the aggregation of Abeta. Molecular Biosystems 5: 986-991.
38. Tsukakoshi K, Abe K, Sode K, Ikebukuro K (2012) Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method. Anal Chem 84: 5542-5547.
39. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, et al. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17: 157-165. (Pubitemid 32409891)
40. Mathews DH, Sabina J, Zuker M, Turner DH (1999) Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 288: 911-940. (Pubitemid 29248642)
41. Gruber AR, Lorenz R, Bernhart SH, Neuböck R, Hofacker IL (2008) The Vienna RNA websuite. Nucleic Acids Res 36: W70-W74.
42. Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, et al. (2006) Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 45: 15157-15167. (Pubitemid 46032442)
43. Bitan G, Fradinger EA, Spring SM, Teplow DB (2005) Neurotoxic protein oligomers-what you see is not always what you get. Amyloid 12: 88-95. (Pubitemid 40978716)
44. Watt AD, Perez KA, Rembach A, Sherrat NA, Hung LW, et al. (2013) Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples. Acta Neuropathol 125: 549-564.
45. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, et al. (2005) Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95: 834-847. (Pubitemid 41567174)
46. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, et al. (2009) Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 48: 1870-1877.
47. Mathura VS, Paris D, Ait-Ghezala G, Quadros A, Patel NS, et al. (2005) Model of Alzheimer's disease amyloid-beta peptide based on a RNA binding protein. Biochem Biophys Res Commun 332: 585-592. (Pubitemid 40725014)
48. Ginsberg SD, Galvin JE, Chiu TS, Lee VM, Masliah E, et al. (1998) RNA sequestration to pathological lesions of neurodegenerative diseases. Acta Neuropathol 96: 487-494. (Pubitemid 28474756)
49. Ginsberg SD, Crino PB, Hemby SE, Weingarten JA, Lee VM-Y, et al. (1999) Predominance of Neuronal mRNAs in Individual Alzheimer's Disease Senile Plaques. Ann Neurol 45: 174-181. (Pubitemid 29072363)
50. Marcinkiewicz M (2002) BetaAPP and furin mRNA concentrates in immature senile plaques in the brain of Alzheimer patients. J Neuropathol Exp Neurol 61: 815-829.
51. Ylera F (1999) Selektion hochaffiner RNA-Moleküle gegen das Alzheimer beta-Amyloid PhD Thesis.
52. Higuchi M, Iwata N, Matsuba Y, Sato K, Sasamoto K, et al. (2005) 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 8: 527-533. (Pubitemid 41007572)